Scholarlink

Purpose <p>The effect of magnesium sulfate on long-term outcomes in patients with sepsis-associated acute kidney injury (SA-AKI) remains unknown. This study aimed to evaluate its association with long-term mortality in SA-AKI patients.</p> Methods <p>We retrospectively analyzed data on patients with SA-AKI from the Medical Information Mart for Intensive Care-IV database. Magnesium sulfate administration after SA-AKI onset was defined as the exposure. Patients were matched 1:1 using propensity score matching (PSM). The primary endpoint was 1-year mortality; secondary endpoints included ICU mortality, in-hospital mortality, 28-day mortality, and major adverse kidney events within 30 days (MAKE30). Associations were assessed using multivariable analyses to calculate hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs).</p> Results <p>Among 16,156 patients, 13,672 received magnesium sulfate. After PSM, 4936 patients (2468 per group) were included. In the PSM cohort, 1-year mortality was lower in the magnesium sulfate group than in the non-use group (41.21% vs. 47.41%; <i>P</i> &lt; 0.001). Magnesium sulfate administration was significantly associated with reduced 1-year mortality (HR, 0.77; 95% CI, 0.71–0.84; <i>P</i> &lt; 0.001), consistent across all subgroup. MAKE30 incidence was also lower in the magnesium sulfate group (33.14% vs. 38.41%; <i>P</i> &lt; 0.001), with a significant associated (OR, 0.83; 95% CI, 0.73–0.94; <i>P</i> = 0.004). Additionally, magnesium sulfate was associated with reduced ICU mortality, in-hospital mortality, and 28-day mortality. Sensitivity analysis performed in the original cohort also demonstrated similar results.</p> Conclusion <p>Magnesium sulfate administration was associated with reduced long-term mortality in SA-AKI patients. These findings warrant confirmation through randomized controlled trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between magnesium sulfate administration and mortality in critically ill patients with sepsis-associated acute kidney injury: a retrospective propensity score-matched cohort study

  • 期刊论文

  • 发表日期：

    2026年2月9日

查看全文
  • Xiang-Jie Duan,
  • Jing-Ru Lan,
  • Ming-Gao Zhu,
  • Jin-Lian Chen,
  • Chang-Yun Zhang,
  • Hai-Yan Yin,
  • Wan-Jie Gu

摘要

Purpose

The effect of magnesium sulfate on long-term outcomes in patients with sepsis-associated acute kidney injury (SA-AKI) remains unknown. This study aimed to evaluate its association with long-term mortality in SA-AKI patients.

Methods

We retrospectively analyzed data on patients with SA-AKI from the Medical Information Mart for Intensive Care-IV database. Magnesium sulfate administration after SA-AKI onset was defined as the exposure. Patients were matched 1:1 using propensity score matching (PSM). The primary endpoint was 1-year mortality; secondary endpoints included ICU mortality, in-hospital mortality, 28-day mortality, and major adverse kidney events within 30 days (MAKE30). Associations were assessed using multivariable analyses to calculate hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs).

Results

Among 16,156 patients, 13,672 received magnesium sulfate. After PSM, 4936 patients (2468 per group) were included. In the PSM cohort, 1-year mortality was lower in the magnesium sulfate group than in the non-use group (41.21% vs. 47.41%; P < 0.001). Magnesium sulfate administration was significantly associated with reduced 1-year mortality (HR, 0.77; 95% CI, 0.71–0.84; P < 0.001), consistent across all subgroup. MAKE30 incidence was also lower in the magnesium sulfate group (33.14% vs. 38.41%; P < 0.001), with a significant associated (OR, 0.83; 95% CI, 0.73–0.94; P = 0.004). Additionally, magnesium sulfate was associated with reduced ICU mortality, in-hospital mortality, and 28-day mortality. Sensitivity analysis performed in the original cohort also demonstrated similar results.

Conclusion

Magnesium sulfate administration was associated with reduced long-term mortality in SA-AKI patients. These findings warrant confirmation through randomized controlled trials.